H.R. 1670: Family Building FEHB Fairness Act
This bill, titled the Family Building FEHB Fairness Act, aims to require federal employee health benefit plans to include coverage for assisted reproductive treatments. Here are the key provisions and implications of the bill:
Fertility Treatment Benefits
The bill amends the United States Code concerning federal employee health benefits by adding the requirement for fertility treatment benefits. Specifically, it includes the following:
- The inclusion of various types of fertility treatments such as:
- Preservation of human oocytes, sperm, or embryos for future use.
- Artificial insemination, which encompasses different methods like intravaginal, intracervical, and intrauterine insemination.
- Assisted reproductive technology, which includes procedures like in vitro fertilization where reproductive materials like eggs and sperm are manipulated.
- Genetic testing of embryos.
- Fertility medications, whether prescribed or over-the-counter.
- Gamete donation, which refers to the donation of sperm or eggs.
- Other related services and treatments that the Office of Personnel Management and the Secretary of Health and Human Services deem appropriate.
Effective Date
The provisions established by this bill would take effect one year after the bill is enacted into law. This timeline allows for the necessary adjustments and preparations by the relevant federal health benefit plans to implement the new coverage requirements.
Overall Impacts
The primary impact of this legislation would be to increase access to fertility treatments for federal employees and their families, helping to address issues related to family building and reproductive health.
Relevant Companies
- PRGO (Perrigo Company) - As a provider of over-the-counter and prescription pharmaceutical products, Perrigo could see an increased demand for fertility medications as insurance coverage expands.
- CAH (Cardinal Health) - A distributor of pharmaceuticals and medical products that may need to adjust its offerings to meet increased demand for fertility-related products.
- MEDP (Medpace Holdings, Inc.) - A clinical contract research organization that may engage in studies or trials related to fertility treatments and could be impacted by more federal funding and interest in reproductive health.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
3 bill sponsors
Actions
3 actions
| Date | Action |
|---|---|
| Sep. 16, 2025 | ASSUMING FIRST SPONSORSHIP - Mr. Walkinshaw asked unanimous consent that he may hereafter be considered as the first sponsor of H.R. 1670, a bill originally introduced by Representative Connolly, for the purpose of adding cosponsors and requesting reprintings pursuant to clause 7 of rule XII. Agreed to without objection. |
| Feb. 27, 2025 | Introduced in House |
| Feb. 27, 2025 | Referred to the House Committee on Oversight and Government Reform. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
